Why the study?
Does pharmacological interference with the cardiac renin-angiotensin system using CE inhibitors improve cardiac outcomes in animal models of ischemia and hypertrophy?
Population
Mammalian heart models including nephrectomized animals, isolated working rat hearts subjected to transient…
Comparison
Converting enzyme inhibitors and/or bradykinin… vs Pure vasodilation or untreated controls
Design
Review
Authors
Loading...
Local CE inhibitor effects in animal ischemia models merit human trials; leaves open translation beyond hemodynamics.
Does pharmacological interference with the cardiac renin-angiotensin system using CE inhibitors improve cardiac outcomes in animal models of ischemia and hypertrophy?
The efficacy of CE inhibitors in congestive heart failure and myocardial ischemia may be partly explained by local intracardiac suppression of angiotensin II generation and bradykinin degradation, independent of systemic hemodynamic effects.
Becker et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: